Pegfilgrastim (Fulphila; Neulasta; Neulasta Onpro; Nyvepria; Udenyca; Ziextenzo) J2506

Pegfilgrastim (J2506) is covered to reduce febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy, with FDA‑recommended administration beginning at least 24 hours after chemotherapy. Same‑day administration is generally not recommended but may be allowed when clearly documented significant patient/caregiver barriers (e.g., lack of transportation) prevent next‑day dosing; documentation must be present in the medical record. Billing requires reporting both the drug HCPCS (J2506 or Q5111) and the appropriate administration CPT (96372 for syringe, 96377 for on‑body injector), noting that 96377 is bundled and not separately payable for outpatient hospital providers.

"Pegfilgrastim (J2506) is indicated to decrease the incidence of infection manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associat..."